Baker Tilly Wealth Management, LLC Neurocrine Biosciences Inc Transaction History

Baker Tilly Wealth Management, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 12, 2023	SELL	$94.11 - $123.02 $14,681 - $19,191	-156 Reduced 3.82%	3,931 $397,000
Q4 2022 Jan 26, 2023	SELL	$106.72 - $127.06 $119,312 - $142,053	-1,118 Reduced 21.48%	4,087 $0
Q3 2022 Oct 20, 2022	SELL	$92.03 - $107.81 $22,639 - $26,521	-246 Reduced 4.51%	5,205 $553,000
Q2 2022 Jul 28, 2022	SELL	$75.79 - $100.07 $32,892 - $43,430	-434 Reduced 7.37%	5,451 $531,000
Q1 2022 Apr 27, 2022	BUY	$72.45 - $94.81 $149,029 - $195,024	2,057 Added 53.74%	5,885 $552,000
Q4 2021 Feb 08, 2022	SELL	$79.65 - $106.22 $36,639 - $48,861	-460 Reduced 10.73%	3,828 $326,000
Q3 2021 Nov 02, 2021	BUY	$86.18 - $99.03 $115,050 - $132,205	1,335 Added 45.21%	4,288 $411,000
Q2 2021 Jul 30, 2021	BUY	$89.43 - $102.27 $77,267 - $88,361	864 Added 41.36%	2,953 $287,000
Q1 2021 Apr 28, 2021	BUY	$87.57 - $119.4 $182,933 - $249,426	2,089 New	2,089 $203,000

638

93.8M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $14.5B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Baker Tilly Wealth Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Baker Tilly Wealth Management, LLC with notifications on news.